Skip to main content
SpringerLink
Log in

Leukocyte Cell-Derived Chemotaxin 2 Amyloidosis (ALECT2)

  • Chapter
Amyloid and Related Disorders

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 1405 Accesses

Abstract

Leukocyte cell-derived chemotaxin 2 amyloidosis (ALECT2) represents the third most common form of renal amyloidosis and has been recently recognized as a frequent cause of hepatic amyloidosis in the USA. The disease shows a restricted geographical and ethnic distribution, and the amyloid deposition in the kidney and liver commonly presents with characteristic pathological features. Nevertheless, ALECT2 amyloidosis has a relatively indolent clinical course which makes the diagnosis difficult. Therefore, an accurate typing of amyloid deposits is required for the appropriate treatment of these patients. We address in this chapter some aspects regarding the pathogenesis of the disease as well as recent advances in the diagnosis of ALECT2 amyloidosis by immunohistochemistry (IHC) and mass spectrometry (MS)-based proteomic analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74(2):218–22.

    Article  CAS  PubMed  Google Scholar 

  2. Murphy CL, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis. 2010;56(6):1100–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Larsen CP, Walker PD, Weiss DT, Solomon A. Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney Int. 2010;77(9):816–9.

    Article  CAS  PubMed  Google Scholar 

  4. Larsen CP, Kossmann RJ, Beggs ML, Solomon A, Walker PD. Clinical, morphologic and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int. 2014;86(2):378–82.

    Article  CAS  PubMed  Google Scholar 

  5. Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014;123(10):1479–82.

    Article  CAS  PubMed  Google Scholar 

  6. Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8(9):1515–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014;86(2):370–7.

    Article  CAS  PubMed  Google Scholar 

  8. Hutton HL, DeMarco ML, Magil AB, Taylor P. Renal leukocyte chemotactic factor 2 (LECT2) amyloidosis in First Nations people in Northern British Columbia, Canada: a report of 4 cases. Am J Kidney Dis. 2014;64(5):790–2.

    Article  CAS  PubMed  Google Scholar 

  9. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen 3rd HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24):4957–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17:101–4.

    Article  CAS  PubMed  Google Scholar 

  11. Yamagoe S, Yamakawa Y, Matsuo Y, et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol Lett. 1996;52:9–13.

    Article  CAS  PubMed  Google Scholar 

  12. Hiraki Y, Inoue H, Kondo J, et al. A novel growthpromoting factor derived from fetal bovine cartilage, chondromodulin II. Purification and aminoacid sequence. J Biol Chem. 1996;271:22657–62.

    Article  CAS  PubMed  Google Scholar 

  13. Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of β-catenin in the liver. Hepatology. 2004;40:167–76.

    Article  CAS  PubMed  Google Scholar 

  14. Segawa Y, Itokazu Y, Inoue N, Saito T, Suzuki K. Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury. Biol Pharm Bull. 2001;24(4):425–8.

    Article  CAS  PubMed  Google Scholar 

  15. Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the liver. Biochim Biophys Acta. 1998;1396(1):105–13.

    Article  CAS  PubMed  Google Scholar 

  16. Yamagoe S, Akasaka T, Uchida T, et al. Expression of a neutrophil chemotactic protein LECT2 in human hepatocytes revealed by immunochemical studies using polyclonal and monoclonal antibodies to a recombinant LECT2. Biochem Biophys Res Commun. 1997;237(1):116–20.

    Article  CAS  PubMed  Google Scholar 

  17. Nagai H, Hamada T, Uchida T, Yamagoe S, Suzuki K. Systemic expression of a newly recognized protein, LECT2, in the human body. Pathol Int. 1998;48(11):882–6.

    Article  CAS  PubMed  Google Scholar 

  18. Uchida T, Nagai H, Gotoh K, et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol Int. 1999;49(2):147–51.

    Article  CAS  PubMed  Google Scholar 

  19. Benson MD. LECT2 amyloidosis. Kidney Int. 2010;77:757–9.

    Article  CAS  PubMed  Google Scholar 

  20. Sato Y, Watanabe H, Kameyama H, et al. Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc. 2004;36(8):2359–61.

    Article  CAS  PubMed  Google Scholar 

  21. Sato Y, Watanabe H, Kameyama H, et al. Changes in serum LECT 2 levels during the early period of liver regeneration after adult living related donor liver transplantation. Transplant Proc. 2004;36(8):2357–8.

    Article  CAS  PubMed  Google Scholar 

  22. Murphy C, Wang S, Kestler D, Larsen C, Benson D, Weiss D, Solomon A. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis. Amyloid. 2011;18 Suppl 1:223–5.

    Article  PubMed  Google Scholar 

  23. Yamagoe S, Kameoka Y, Hashimoto K, Mizuno S, Suzuki K. Molecular cloning, structural characterization, and chromosomal mapping of the human LECT2 gene. Genomics. 1998;48(3):324–9.

    Article  CAS  PubMed  Google Scholar 

  24. Dogan A, Theis JD, Vrana JA, et al. Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2) (abstract OP-058). Amyloid. 2010;17 Suppl 1:69–70.

    Google Scholar 

  25. Kameoka Y, Yamagoe S, Hatano Y, Kasama T, Suzuki K. Val58Ile polymorphism of the neutrophil chemoattractant LECT2 and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 2000;43(6):1419–20.

    Article  CAS  PubMed  Google Scholar 

  26. Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol. 1989;2(4):372–7.

    CAS  PubMed  Google Scholar 

  27. Buck FS, Koss MN. Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol. 1991;22:904–7.

    Article  CAS  PubMed  Google Scholar 

  28. Damlaj M, Amre R, Wong P, How J. Hepatic ALECT2-amyloidosis causing portal hypertension and recurrent variceal bleeding: a case report and review of the literature. Am J Clin Pathol. 2014;141(2):288–91.

    Article  PubMed  Google Scholar 

  29. Chandan VS, Shah SS, Lam-Himlin DM, et al. Globular hepatic amyloid is highly sensitive and specific for LECT2 amyloidosis. Am J Surg Pathol. 2015;39:558–64.

    Article  PubMed  Google Scholar 

  30. Kanel GC, Uchida T, Peters RL. Globular hepatic amyloid-an unusual morphologic presentation. Hepatology. 1981;1:647–52.

    Article  CAS  PubMed  Google Scholar 

  31. Agaram N, Shia J, Klimstra DS, et al. Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance. Hum Pathol. 2005;36:845–49.

    Article  PubMed  Google Scholar 

  32. Makhlouf HR, Goodman ZD. Globular hepatic amyloid: an early stage in the pathway of amyloid formation. A study of 20 new cases. Am J Surg Pathol. 2007;31(10):1615–21.

    Article  PubMed  Google Scholar 

  33. Pilgaard J, Fenger C, Schaffalitzky de Muckadell OB. Globular amyloid deposits in the liver. Histopathology. 1993;23(5):479–80.

    Article  CAS  PubMed  Google Scholar 

  34. Demirhan B, Bilezikci B, Kiyici H, Boyacioglu S. Globular amyloid deposits in the wall of the gastrointestinal tract: report of six cases. Amyloid. 2002;9(1):42–6.

    Article  PubMed  Google Scholar 

  35. Hemmer PR, Topazian MD, Gertz MA, Abraham SC. Globular amyloid deposits isolated to the small bowel: a rare association with AL Amyloidosis. Am J Surg Pathol. 2007;31:141–5.

    Article  PubMed  Google Scholar 

  36. Comenzo RL. LECT2 makes the amyloid list. Blood. 2014;123(10):1436–7.

    Article  CAS  PubMed  Google Scholar 

  37. Picken MM. Alect2 amyloidosis: primum non nocere (first, do not harm). Kidney Int. 2014;86:229–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Oana Madalina Mereuta MD, PhD

  2. Nephropath, 10810 Executive Center Drive, Little Rock, AR, 72211, USA

    Chris P. Larsen MD

  3. Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Ahmet Dogan MD, PhD

Authors
  1. Oana Madalina Mereuta MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris P. Larsen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmet Dogan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Dogan MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA

    Maria M. Picken

  2. Department of Pathology, LSU Health Shreveport, Shreveport, Louisiana, USA

    Guillermo A. Herrera

  3. Department of Pathology and Laboratory Medicine, Department of Pathology and Laboratory Medicine, New York, New York, USA

    Ahmet Dogan

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mereuta, O.M., Larsen, C.P., Dogan, A. (2015). Leukocyte Cell-Derived Chemotaxin 2 Amyloidosis (ALECT2). In: Picken, M., Herrera, G., Dogan, A. (eds) Amyloid and Related Disorders. Current Clinical Pathology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-19294-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19294-9_4

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-19293-2

  • Online ISBN: 978-3-319-19294-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation